Nuformix (LON:NFX) Trading Down 7.7% – Here’s Why

Nuformix plc (LON:NFX) was down 7.7% during mid-day trading on Thursday . The stock traded as low as GBX 0.23 and last traded at GBX 0.23. Approximately 1,843,170 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 33,943,625 shares. The stock had previously closed at GBX 0.25.

Nuformix Stock Up 5.3%

The stock’s 50-day moving average price is GBX 0.26 and its 200 day moving average price is GBX 0.23. The firm has a market cap of £5.49 million, a price-to-earnings ratio of -6.62 and a beta of 1.22.

Nuformix (LON:NFX) last issued its quarterly earnings results on Tuesday, January 27th. The company reported GBX (0.04) earnings per share (EPS) for the quarter.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.